Takeda's takhzyro® (lanadelumab) demonstrated positive results in the prevention of hae attacks in first and only open-label phase 3 trial in children ages 2 to

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced late-breaking data from the phase 3 spring study (nct04070326) presented at the european academy of allergy and clinical immunology (eaaci) hybrid congress 2022, demonstrating positive results of takhzyro® (lanadelumab) for preventing hereditary angioedema (hae) attacks in patients 2 to
TAK Ratings Summary
TAK Quant Ranking